公开(公告)号：US20130072720A1

公开(公告)日：2013-03-21

申请号：US13337661

申请日：2011-12-27

Applicant: HSU-SHAN HUANG ,  JENN-HAUNG LAI ,  LING-JUN HO ,  FENG-CHENG LIU

Inventor： HSU-SHAN HUANG ,  JENN-HAUNG LAI ,  LING-JUN HO ,  FENG-CHENG LIU

IPC: C07C235/56

CPC classification number: C07C235/56

Abstract: A pharmaceutical composition including 2-hydroxy-N—[3-(trifluoromethyl)phenyl]benzamide and used for treatment of osteoarthritis is revealed. The pharmaceutical composition inhibits tumor necrosis factor (TNF) induced interferon regulatory factor (IRF). The activated IRF stimulates chondrocytes to secret matrix metalloproteinases, inducible nitric oxide synthase (iNOS), aggrecanases, etc. This leads to loss of collagen II and further causes degradation of proteoglycan. By suppression of signaling pathways of interferon regulatory factor, symptoms are relieved and osteoarthritis is treated.

Abstract translation: 揭示了用于治疗骨关节炎的包含2-羟基-N- [3-（三氟甲基）苯基]苯甲酰胺的药物组合物。 该药物组合物抑制肿瘤坏死因子（TNF）诱导的干扰素调节因子（IRF）。 激活的IRF刺激软骨细胞分泌基质金属蛋白酶，诱导型一氧化氮合酶（iNOS），聚集蛋白聚糖蛋白聚糖酶等。这导致胶原蛋白II的丧失，并进一步导致蛋白聚糖的降解。 通过抑制干扰素调节因子的信号通路，缓解症状并治疗骨关节炎。